Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma: A Comprehensive Analysis of Individual Patient Data from Randomized GHSG Trials.
P J Bröckelmann, H Müller, M Fuchs, S Gillessen, D A Eichenauer, S Borchmann, A S Jacob, K Behringer, J Momotow, J Ferdinandus, B Böll, X Yang, C Kobe, H-T Eich, C Baues, W Klapper, A Engert, P Borchmann, B von Tresckow
{"title":"Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma: A Comprehensive Analysis of Individual Patient Data from Randomized GHSG Trials.","authors":"P J Bröckelmann, H Müller, M Fuchs, S Gillessen, D A Eichenauer, S Borchmann, A S Jacob, K Behringer, J Momotow, J Ferdinandus, B Böll, X Yang, C Kobe, H-T Eich, C Baues, W Klapper, A Engert, P Borchmann, B von Tresckow","doi":"10.1016/j.annonc.2024.12.009","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to evaluate the correlation of progression-free (PFS) and overall survival (OS) after first-line treatment of classical Hodgkin lymphoma (HL) and the potential of PFS to serve as a surrogate parameter for OS.</p><p><strong>Patients and methods: </strong>We analyzed individual patient data obtained during and after treatment with polychemotherapy within nine randomized phase III trials (GHSG HD7-HD15) between 01/93 - 08/18. Effects of 16 experimental treatments on PFS and OS on trial level were evaluated by estimation of the treatment effects with Cox proportional hazards (PH) regression and a linear weighted least squares regression. On the patient level, marginal Cox PH models for multiple endpoints were applied according to the Wei-Lin-Weissfeld method.</p><p><strong>Results: </strong>At least one PFS and OS event was recorded in 1,682 and 1,064 of 10,605 patients, respectively. At trial level there was a strong correlation of treatment effects on PFS and OS (weighted Pearson r= 0.72, R<sup>2</sup>= 0.54, P< 0.001). At patient level, moderate to strong correlation of treatment effects on PFS and OS was confirmed with Pearson r ranging between 0.61 - 0.85 (each P< 0.001) and overall r= 0.74. A regression model accounting for different types of experimental treatments and historical progress over trial generations reached very strong correlation (R<sup>2</sup>= 0.93). Applying this model to data from the contemporary first-line ECHELON-1 trial allowed for prediction of OS from PFS (prognosticated ln[HR(OS)]= -0.68 as compared to observed ln[HR(0.59)]= -0.53).</p><p><strong>Conclusion: </strong>In first-line trials of HL, PFS and OS as well as treatment effects and prognostic effects on PFS and OS are strongly correlated. PFS thereby predicts treatment effects on OS to a high degree and many years before OS can be reliably evaluated.</p>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":" ","pages":""},"PeriodicalIF":56.7000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.annonc.2024.12.009","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: We aimed to evaluate the correlation of progression-free (PFS) and overall survival (OS) after first-line treatment of classical Hodgkin lymphoma (HL) and the potential of PFS to serve as a surrogate parameter for OS.
Patients and methods: We analyzed individual patient data obtained during and after treatment with polychemotherapy within nine randomized phase III trials (GHSG HD7-HD15) between 01/93 - 08/18. Effects of 16 experimental treatments on PFS and OS on trial level were evaluated by estimation of the treatment effects with Cox proportional hazards (PH) regression and a linear weighted least squares regression. On the patient level, marginal Cox PH models for multiple endpoints were applied according to the Wei-Lin-Weissfeld method.
Results: At least one PFS and OS event was recorded in 1,682 and 1,064 of 10,605 patients, respectively. At trial level there was a strong correlation of treatment effects on PFS and OS (weighted Pearson r= 0.72, R2= 0.54, P< 0.001). At patient level, moderate to strong correlation of treatment effects on PFS and OS was confirmed with Pearson r ranging between 0.61 - 0.85 (each P< 0.001) and overall r= 0.74. A regression model accounting for different types of experimental treatments and historical progress over trial generations reached very strong correlation (R2= 0.93). Applying this model to data from the contemporary first-line ECHELON-1 trial allowed for prediction of OS from PFS (prognosticated ln[HR(OS)]= -0.68 as compared to observed ln[HR(0.59)]= -0.53).
Conclusion: In first-line trials of HL, PFS and OS as well as treatment effects and prognostic effects on PFS and OS are strongly correlated. PFS thereby predicts treatment effects on OS to a high degree and many years before OS can be reliably evaluated.
期刊介绍：
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
